β肾上腺素能受体阻滞剂奈必洛尔的最新临床应用进展  

Current advance in clinical application of the β-adrenoceptor antagonist nebivolol

作　　者：贾静[1] 张伟华[2] 冷晓宁[1] 

机构地区：[1]哈尔滨医科大学,哈尔滨150086 [2]哈尔滨医科大学附属第一医院心内科,哈尔滨150001

出　　处：《中国新药杂志》2011年第1期5-9,共5页Chinese Journal of New Drugs

摘　　要：奈必洛尔(nebivolol,Neb)是第三代β肾上腺素能受体阻滞剂(β受体阻滞剂),它不同于其他β受体阻滞剂:它具有强的β1受体阻滞、一氧化氮(NO)介导的血管扩张以及逆转内皮功能异常的作用。在欧洲Neb已用于治疗原发性高血压和年龄≥70岁的稳定型轻中度慢性心力衰竭(CHF)。在Neb的药效学和药动学方面,已有相关实验证明:Neb能有效地降低血压,而且能有效地降低中老年CHF的死亡率和住院率。文中主要从Neb的药效学、药动学及相关实验研究方面,阐明Neb在治疗原发性高血压和中老年CHF的进展情况以及展望其在国内的临床应用。Nebivolol（Neb） is a third generation β-adrenoceptor antagonist.Different from other β-adrenoceptor antagonists,it possesses highly selective β1-adrenoceptor antagonist activity and NO-mediated vasodilator effect,and can reverse endothelial dysfunction.Neb has been used in Europe for the treatment of essential hypertension and stable mild-moderate chronic heart failure（CHF） in elderly patients aged ≥70 years.From its pharmacodynamics and pharmacokinetics,Neb can effectively lower blood pressure,and decrease the endpoint of mortality and hospital admission in elderly patients with cardiovascular diseases.In this paper,we introduced the treatment progress of the new β-blocker Neb for hypertension and chronic heart failure,and described its pharmacodynamics,pharmacokinetics,and related experimental research and its clinical prospects in our country.

关 键 词：奈必洛尔 高血压 慢性充血性心力衰竭 Β受体阻滞剂 

分 类 号：R972.5[医药卫生—药品]